Table 5.

Risk Difference of Major Cardiovascular Events for Rosuvastatin Among Patients Aged Less Than 80 Years in “Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin” (Multiple Countries, 2003–2008), Before and After Standardizing to the Imputed Cohort and the Complete Case Cohort From the Clinical Practice Research Datalink (United Kingdom, 2001–2014), without Selection Weight Truncation

Year From Randomization	JUPITER		JUPITER, Standardized to the Imputed Cohort		JUPITER, Standardized to the Complete Case Cohort
	Risk Difference, %	95% CI	Risk Difference, %	95% CI	Risk Difference, %	95% CI
1	−0.5	−0.8, −0.3	−0.5	−0.8, −0.2	−0.4	−1.0, 0.1
2	−1.1	−1.5, −0.6	−0.9	−1.3, −0.5	−0.8	−1.6, −0.1
3	−2.0	−2.8, −1.1	−1.7	−2.8, −0.6	−1.9	−3.5, −0.3
4	−2.8	−4.1, −1.6	−2.7	−3.6, −1.8	−2.9	−5.3, −0.6

Abbreviation: CI, confidence interval; JUPITER, Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin.